Literature DB >> 19097558

RSV infection in the adult population.

Julio A Ramirez1.   

Abstract

RSV is a significant and unrecognized cause of seasonal RTIs in adults, accounting for as much as 25 percent of excess wintertime mortality usually attributed to influenza. Nearly 80 percent of RSV-associated underlying respiratory and circulatory deaths occur among the elderly, and RSV is estimated to account for about 180,000 hospital admissions each year at a cost exceeding $1 billion. RSV also is recognized as an important cause of viral pneumonia in adults. Preventive measures, such as hand washing, are paramount, especially in hospitals and nursing homes where many immunocompromised patients reside. When RSV is circulating, it is advisable to minimize contact between high-risk patients and children.

Entities:  

Mesh:

Year:  2008        PMID: 19097558

Source DB:  PubMed          Journal:  Manag Care        ISSN: 1062-3388


  4 in total

1.  Respiratory syncytial virus market.

Authors:  Shane Storey
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 2.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection.

Authors:  Allison L Miller; Gary P Sims; Yambasu A Brewah; Marlon C Rebelatto; Jennifer Kearley; Ebony Benjamin; Ashley E Keller; Philip Brohawn; Ronald Herbst; Anthony J Coyle; Alison A Humbles; Roland Kolbeck
Journal:  J Infect Dis       Date:  2012-01-18       Impact factor: 5.226

Review 4.  Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance.

Authors:  Julian W Tang; Tommy T Lam; Hassan Zaraket; W Ian Lipkin; Steven J Drews; Todd F Hatchette; Jean-Michel Heraud; Marion P Koopmans
Journal:  Lancet Infect Dis       Date:  2017-04-28       Impact factor: 25.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.